JAK2V617F阳性骨髓纤维化患者SLAMF7high单核细胞增多且elotuzumab具治疗潜力
该横断面研究评估了健康对照、伴或不伴骨髓纤维化(MF)的骨髓增殖性肿瘤(MPN)患者外周血SLAMF7high单核细胞比例,发现携带JAK2V617F的MF患者该比例显著升高且与等位基因负荷正相关,SLAMF7high单核细胞的JAK2V617F负荷更高,elotuzumab(Elo)在体外抑制纤维细胞分化并在人源化小鼠中改善MF和脾肿大。
要点
- 携带JAK2V617F的MF患者外周血SLAMF7high单核细胞比例显著升高,且与JAK2V617F等位基因负荷正相关。
- 血清IL-1ra浓度与SLAMF7high单核细胞比例及JAK2V617F等位基因负荷显著相关。
- SLAMF7high单核细胞的JAK2V617F等位基因负荷显著高于SLAMF7low单核细胞,Elo在体外抑制纤维细胞分化并改善人源化小鼠MF和脾肿大。
核心结论
- 携带JAK2V617F的MPN患者中,SLAMF7high单核细胞增加且JAK2V617F等位基因负荷更高,与MF发生相关,Elo可能成为该类患者的治疗药物。
研究设计与样本
- 横断面研究,比较健康对照、伴MF的MPN患者及不伴MF的MPN患者外周血SLAMF7high单核细胞比例,并进行体外实验和人源化NOG小鼠实验。
主要发现
- 携带JAK2V617F的MF患者SLAMF7high单核细胞比例显著升高,且与JAK2V617F等位基因负荷正相关。
- 血清IL-1ra浓度与SLAMF7high单核细胞比例及JAK2V617F等位基因负荷显著相关。
- SLAMF7high单核细胞的JAK2V617F等位基因负荷显著高于SLAMF7low单核细胞。
- Elo在体外独立抑制来自健康对照和MF患者的纤维细胞分化。
- Elo改善人源化NOG小鼠中由罗米司亭给药诱导的MF和脾肿大。
临床怎么用
- SLAMF7high单核细胞和IL-1ra可能作为MF发生的无创标志物。
- SLAMF7high单核细胞可能成为elotuzumab的潜在靶点。
- Elo可能用于携带JAK2V617F的MF患者。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monocyte-derived fibrocytes recently garnered attention because the novel pathogenesis of myelofibrosis (MF), and suppression of fibrocyte differentiation by serum amyloid P remarkably improved MF. We previously revealed that human fibrocytes highly expressed signaling lymphocytic activation molecule F7 (SLAMF7) compared with macrophages and that SLAMF7high monocytes in the peripheral blood (PB) of MF patients were significantly elevated relative to those in healthy controls (HCs). In this study, we evaluated SLAMF7high monocyte percentage in the PB of HCs, myeloproliferative neoplasm (MPN) patients with MF, and MPN patients without MF by using a cross-sectional approach. We found that MPN patients with MF who harbored JAK2V617F had a significantly elevated SLAMF7high monocyte percentage, which correlated positively with the JAK2V617F allele burden. In addition, the serum concentration of interleukin-1ra (IL-1ra) was significantly correlated with the SLAMF7high monocyte percentage and JAK2V617F allele burden. These findings suggest that both SLAMF7high monocytes and IL-1ra could be useful noninvasive markers of MF onset. Furthermore, the JAK2V617F allele burden of SLAMF7high monocytes was significantly higher than that of SLAMF7low monocytes and could be a potential target of elotuzumab (Elo), an anti-SLAMF7 antibody used for treating multiple myeloma. Elo independently inhibited differentiation of fibrocytes derived not only from HCs but also from MF patients in vitro. Elo also ameliorated MF and splenomegaly induced by romiplostim administration in humanized NOG mice. In conclusion, an increase of SLAMF7high monocytes with higher JAK2V617F allele burden was associated with the onset of MF in MPN patients harboring JAK2V617F, and Elo could be a therapeutic agent for MPN patients with MF who harbor JAK2V617F.
引用
- Maekawa T, Kato S, Kawamura T, et al. Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab. Blood. 2019. PMID: 31270105. doi:10.1182/blood.2019000051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。